## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.59 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-6.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($93.06)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Goldman Sachs initiates coverage on Revvity stock with Neutral rating By Investing.com**
- Source: Investing.com South Africa | 20251209T080837 | Neutral | Relevance: 98%
-  Goldman Sachs has initiated coverage on Revvity Inc. (NYSE:RVTY) with a Neutral rating and a price target of $105.00, implying a 5% upside. The firm cited Revvity's exposure to early-stage biotech funding and the China diagnostics market as potential headwinds, expecting these challenges to persist until 2026. Despite this, Goldman Sachs highlighted company-specific growth drivers that could largely offset these weaknesses, particularly a faster recovery for its consumables-focused portfolio if drug discovery activity increases.

**2. Bollard Group LLC Purchases Shares of 18,439 Revvity Inc. $RVTY**
- Source: MarketBeat | 20251207T101531 | Bullish | Relevance: 98%
-  Bollard Group LLC recently acquired 18,439 shares of Revvity Inc. (NYSE:RVTY) valued at approximately $1,783,000 during the second quarter. This move is part of broader institutional interest, with several other firms increasing their holdings in Revvity. Analysts currently rate Revvity as a "Moderate Buy" with a consensus target price of $114.75, following recent positive earnings reports and a declared quarterly dividend.

**3. Invesco Ltd. Acquires 452,343 Shares of Revvity Inc. $RVTY**
- Source: MarketBeat | 20251208T111946 | Somewhat-Bullish | Relevance: 98%
-  Invesco Ltd. increased its stake in Revvity Inc. (NYSE:RVTY) by 25.8% during the second quarter, acquiring an additional 452,343 shares. This raises Invesco's total holdings to 2,207,202 shares, valued at approximately $213.48 million, representing 1.90% of Revvity. Other institutional investors have also adjusted their positions in Revvity, which recently announced a stock repurchase plan and a quarterly dividend.

**4. Goldman Sachs initiates coverage on Revvity stock with Neutral rating By Investing.com**
- Source: Investing.com Canada | 20251209T080917 | Neutral | Relevance: 97%
-  Goldman Sachs has initiated coverage on Revvity Inc. (NYSE:RVTY) with a Neutral rating and a price target of $105.00, citing the company's significant exposure to early-stage biotech funding and China diagnostics markets, which are expected to remain challenging. Despite these headwinds, Goldman Sachs noted Revvity's company-specific growth drivers and a consumables-focused portfolio that could see a faster recovery. The investment bank anticipates that ongoing market challenges will temper the growth potential of Revvity's specific drivers, leading to limited upside for fiscal year 2026 estimates.

**5. Goldman Sachs initiates coverage on Revvity stock with Neutral rating**
- Source: Investing.com India | 20251209T082450 | Neutral | Relevance: 96%
-  Goldman Sachs has initiated coverage on Revvity Inc. (NYSE:RVTY) with a Neutral rating and a $105.00 price target, suggesting a 5% upside. The investment bank cited Revvity's exposure to early-stage biotech funding and China diagnostics markets as challenges, expecting them to persist until 2026. Despite these headwinds, Goldman Sachs believes company-specific growth drivers, particularly its consumables-focused portfolio, could largely offset potential weaknesses, though market headwinds are expected to dilute overall growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.7% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (10.5%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.59 indicates undervaluation relative to growth. Forward P/E 18.6x stretched relative to 8% growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.5B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 10.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.59 |
| Forward P/E | 18.6 |
| Current P/E | 20.1 |
| YoY Growth | 7.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.9% to -1.8% (-6.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.8pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.77% (CS: 46) | Neutral |
| RSI_14 | 51.9 | Neutral |
| MACD Histogram | -0.23 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.038x | Above |
| vs SMA200 | 1.035x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $98.78
- **Stop Loss:** $93.06 (5.8% risk)
- **Target:** $110.22 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 52
- **Position Value:** $5,136.56
- **Portfolio %:** 5.14%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*